The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Would like to claim that the £47.47 K buy was mine but alas no. Had a late night last night so going to head back to bed after I've got the kids out to school. Hope I don't miss any fireworks or fun. LOL ATB
Guess all the trades today answer your question(60ish). Few nice buys in there as well. GL
Haven't been here for long. Do folk reinvest their divis? Seems to rise in the afternoon here in my limited experience. Enjoy your evening.
Must admit i was sorely tempted(is that an oxymoron) to sell some today. But i'm going to stick to my guns. A blue day today and once the new FD is in place, hopefully he/she's spouse/son/daughter/dog will buy some shares. Div payment tomorrow. All good in the world of IDH(at least in my head). GL
That £3.00 of yours suddenly looking a whole lot nearer GL.
was £2.6150 for a while and nobody was for selling and now it's dropped back to £2.5825 lol
A new Finacial D means job loss, inevitable.
They are taking their time in finding a new Financial Director. There are plenty around. The current guy will, I understand, be there for six months beyond the announcement of his resignation.
So tempted to stick everything i have left into this Company. So i'm going to do it.. 300 i'm out.
Somebody bought 112,500 at 2.60p yesterday just before the close of business. British Bulls now have a buy confirmed recommendation http://www.britishbulls.com/StockPage.asp?CompanyTicker=IDH&MarketTicker=Health%20Care&TYP=S Very quiet bb. Been checking the spread here - almost Thorntons like lol
Not usually something I would pay heed to but for what it's worth http://sharedealing.nandp.co.uk/broker-views/IDH/Immunodiagnostic-Systems-Holdings still a buy and a hold according to the majority.
finnCap is one of those currently reviewing its forecasts, even though it only updated them six weeks ago. "Assuming that margins are maintained, and the costs remain as per our model, then sales of £47.9m would lead to PBT [profit before tax] of £8.3m and adjusted EPS [earnings per share] of 44.0p (22.7p basic)," postulated finnCap's Keith Redpath. "Whilst the current share price places IDS on un-demanding multiples, even with reduced expectations, concerns over IDS's ability to continue to grow iSYS revenues significantly remains. At best the shares are a Hold," Redpath believes. House broker Peel Hunt has gone ahead and chopped its earnings forecasts. It now predicts profit before tax of £9.4m for the current financial year, down from its previous forecast of £13.5m. The EPS forecast is chopped to 23.5p from 33.6p. "On the bright side placements of ISYS are tracking ahead of our expectations and remain the key driver of strategic value," said Peel Hunt, which has retained its "buy" recommendation despite chopping its price target from 450p to 375p.
IDS-iSYS revenues grew strongly by 15% over the prior period whereas manual revenues declined, as expected, by 19%, reflecting the continuing competitive environment of this market place and the transition of certain laboratories from manual to automated testing. A total of 32 IDS-iSYS instruments have been sold or placed to reagent rental IDS end user customers during the period, net of returns, representing an increase of 18% over the installed base as at 31 March 2012. Panmure Gordon reacted to the trading update by downgrading its full-year sales forecast by some 7%, and next year's forecast by 9%. As a result of this, the broker's price target for the stock has been chopped to 350p from 400p, although the "buy" recommendation is retained, "as we continue to see value in the platform". "Looking at valuation (1.2x Revenues & 6.1x PE [price/earnings]), it is obvious to us that perhaps further market downgrades to forecasts will materialise in coming months," the broker said. "The business remains in choppy waters, with the well-known entrance this year of a number of larger competitors in IDS's relatively small market. The macro environment, particularly in Europe, is not helping either," Panmure Gordon continued. "Despite the challenges, we believe there are still significant niches in the market (smaller laboratories that cannot afford the larger fully integrated machines which Roche, Abbott and Siemens sell, hospital labs or teaching hospitals that require better precision etc) which the company can target to boost its recovery. Overall we have been comforted from what we heard in our meeting that Patrik Dahlen and his vision seems sensible to us," Neophytou concluded.
Immunodiagnostic Systems (IDS), a producer of manual and automated specialist diagnostic testing kits, reported a decline in unaudited revenues for the five months ended August 31st. Turnover was down to £19.9m from £22.7m in the same period the previous year, partly the result of an adverse £0.5m impact of exchange rate differences between the two periods. It expects the impact of exchange rates compared to the prior year to continue to have an adverse effect on full year revenues, but the impact on earnings is expected to be mitigated to some extent as the cost base of the group's foreign currency denominated operations will generate a favourable variance. The five month period in 2011 included a £0.4m one off licence fee and no such fees were generated in the comparable period to August 31st 2012. On a like-for-like basis revenues fell by 9% compared to the same period the previous year. Broker Panmure Gordon said the 12% revenue decline was worse than expected. "Although automated revenues grew 15%, this was considerably lower than our expectation of [greater than] 30% growth," Panmure analyst Savvas Neophytou said. "On outlook the company guided to FY2013 [fiscal 2013] revenues of £48-50m, which is below our forecast of £55m," the broker added. More positively, the recent launches of 1,25 Dihydroxy vitamin D, renin and aldosterone automated assays have been well received in the market, despite these occurring later than planned.
Average revenue per instrument from the Group's reagent rental accounts was £79,000 (31 March 2012: £84,000). The volume of IDS-iSYS system placements with reagent rental IDS end user customers reported for the last two financial years has averaged 80 systems per year and it is expected to be at a similar level in the current financial year. Operating costs are being carefully managed and remain in line with our expectations for the full year. Importantly, the Company has continued to be strongly cash generative over the first five months of the current financial year. Unaudited net cash as at 10 September 2012 was £11.0m, an increase of £4.2m from the reported net cash balances at 31 March 2012. Outlook The Board expects the impact of exchange rates compared to the prior year to continue to have an adverse effect on full year revenues. The earnings impact of this exchange difference is expected to be mitigated to some extent as the cost base of the Group's foreign currency denominated operations will generate a favourable variance. The anticipated decline in manual vitamin D test volumes combined with more competitive pricing in this market continues to be in line with our expectations. The planned increase in IDS-iSYS derived revenues from new placements and an increasing number of automated assays, whilst encouraging, is however not materialising at a rate that will fully offset the ongoing manual revenue decline in the current financial year and accordingly the Board's expectation is that revenues for the year ending 31 March 2013 will be in the range of £48m to £50m.
Trading Update Unaudited revenues for the five months ended 31 August 2012 are £19.9m (2011: £22.7m) and reflect an adverse £0.5m impact of exchange differences between the two periods. The following revenue comparisons in this statement are reported at constant exchange rates. Like-for-like revenues reduced by 9% over the prior period. The five month period to 31 August 2011 included a £0.4m one off licence fee and no such fees were generated in the comparable period to 31 August 2012. This licence fee has been excluded from prior period revenue to calculate the like-for-like revenue variance. IDS-iSYS revenues (excluding the one off licence fee in 2011) grew strongly by 15% over the prior period whereas manual revenues declined, as expected, by 19%, reflecting the continuing competitive environment of this market place and the transition of certain laboratories from manual to automated testing. A total of 32 IDS-iSYS instruments have been sold or placed to reagent rental IDS end user customers during the period, net of returns, representing an increase of 18% over the installed base as at 31 March 2012. The Board has recently reviewed the criterion that is used to both classify instrument placements and also to define a live system. This has resulted in the following adjustments to the Group's installed base of IDS-iSYS instruments.
Immunodiagnostic Systems Holdings PLC AGM Statement and Trading Update Immunodiagnostic Systems Holdings PLC ("IDS" or "the Company" or "the Group"), a leading producer of manual and automated specialist diagnostic testing kits and instrumentation for the clinical and research markets, will today hold its Annual General Meeting at noon at its registered office at 10 Didcot Way, Boldon Business Park, Boldon, Tyne & Wear, NE35 9PD. At the meeting Chairman, Anthony Martin, will make the following statement to shareholders. Strategy update The Board continues to believe that IDS-iSYS' carefully selected portfolio of specialised assay panels provides the Group with a compelling market opportunity that will appeal to a range of laboratories which will be increasingly enhanced as further assays are successively launched. The recent launches of 1,25 Dihydroxy vitamin D, renin and aldosterone automated assays have been well received in the market, although the timing of some of the launches were later than planned. There have also been some significant account openings with other automated assays, particularly IGF-1. As part of the Group's strategy of expanding its automated assay menu, all of these new automated assays have helped the placement rate of IDS-iSYS systems and reinforced the Board's belief in this core element of the Group's strategy. The Board was delighted to announce the appointment of Patrik Dahlen as Chief Executive Officer in July 2012. Patrik will provide additional detail as to the Group's strategy at the interim results which are expected to be released in November 2012.
http://www.investegate.co.uk/Article.aspx?id=201209140700102534M
in the recovery position? Dunno but has been a good week here after VERY lean times, phew! Could be random, or perhaps news imminent - happy whatever. GL all
pair of hands?http://www.investegate.co.uk/article.aspx?id=201207020700145855G
Valuation: Not a time for over optimism A cash-flow indicative value to 2015 indicates about 300p at a 10% growth rate; Edison’s internal model is more pessimistic than broker estimates. Longer term, IDS needs to get a critical mass of iSYS into the US to have a chance and this will need energy and lots of cash once FDA approvals are gained. The French and German markets may not offer a robust independent future; deals are needed
Anyone have a view on why the CEO departed so quickly. This does not bode well IMHO. Others intake would be appreciated
"Costs are being continuously monitored to ensure resources are targeted at the key drivers for the business which are development productivity and niche marketing and sales activities to target the customer base benefiting most from the group's products." The share price fell 7.14% to 260p by 12:53.
The dividend for the year was increased from 2.50p to 2.75p following a period of strong cash generation. In a statement the company said: "Trading for the first three months of the current financial year is in line with management expectations and we have continued to place additional IDS-iSYS systems. More recently we have secured new accounts for both our automated IDS-iSYS test for 1,25 dihydroxy vitamin D and also for our new hypertension assays launched within the past few weeks. "We are working hard to continue to build the company and increase shareholder value in what is a challenging business environment. Despite the much more competitive market, we have increased our vitamin D revenues while at the same time diversifying the product range to broaden the appeal of the IDS-iSYS system and reduce the influence of changes in the vitamin D market.